Advertisement

Cross-Sectional Imaging Indexes for Crohn’s Disease

  • Jordi RimolaEmail author
Chapter

Abstract

Objective assessment of disease activity and complications in Crohn’s disease (CD) is critical to ensure accurate diagnosis and assessment of therapeutic response in both clinical practice and research. For recent clinical trials, patient selection and trial endpoints have been based on clinical symptoms and mucosal inflammation of the terminal ileum and large bowel determined on ileocolonoscopy. However, cross-sectional imaging methods have definite advantages over ileocolonoscopy and are potentially superior for use in CD clinical practice and trials. The development and validation of objective indexes of activity based on cross-sectional imaging will improve patient selection and assessment of the efficacy of new treatments.

Keywords

Crohn’s disease Activity Magnetic resonance Magnetic resonance enterography Computed tomography enterography Perianal disease 

References

  1. 1.
    Best W, Becktel J, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–44.PubMedGoogle Scholar
  2. 2.
    Peyrin-Biroulet L, Reinisch W, Colombel J-F, Mantzaris GJ, Kornbluth A, Diamond R, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut. 2014;63:88–95.CrossRefGoogle Scholar
  3. 3.
    Lémann M, Mary JY, Colombel JF, Duclos B, Soule JC, Lerebours E, et al. A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology. 2005;128:1812–8.CrossRefGoogle Scholar
  4. 4.
    Allez M, Lemann M, Cattan P, Jian R, Modigliani R. Long term outcome of patients with active Crohn’s disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol. 2002;97:947–53.PubMedGoogle Scholar
  5. 5.
    Gomollón F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. 2017;11:3–25.CrossRefGoogle Scholar
  6. 6.
    Jauregui-Amezaga A, Rimola J, Ordás I, Rodríguez S, Ramírez-Morros A, Gallego M, et al. Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn’s disease in the era of biologics. Gut. 2015;64:1397–402.CrossRefGoogle Scholar
  7. 7.
    Samuel S, Bruining DH, Loftus EV, Becker B, Fletcher JG, Mandrekar JN, et al. Endoscopic skipping of the distal terminal ileum in Crohn’s disease can lead to negative results from ileocolonoscopy. Clin Gastroenterol Hepatol. 2012;10:1253–9.CrossRefGoogle Scholar
  8. 8.
    Solem CA, Loftus EV, Fletcher JG, Baron TH, Gostout CJ, Petersen BT, et al. Small-bowel imaging in Crohn’s disease: a prospective, blinded, 4-way comparison trial. Gastrointest Endosc. 2008;68:255–66.CrossRefGoogle Scholar
  9. 9.
    García-Bosch O, Ordás I, Aceituno M, Rodríguez S, Ramírez AM, Gallego M, et al. Comparison of diagnostic accuracy and impact of MRI and colonoscopy for the management of Crohn’s disease. J Crohns Colitis. 2016;10:663–9.CrossRefGoogle Scholar
  10. 10.
    Siddiki HA, Fidler JL, Fletcher JG, Burton SS, Huprich JE, Hough DM, et al. Prospective comparison of state-of-the-art MR enterography and CT enterography in small-bowel Crohn’s disease. AJR Am J Roentgenol. 2009;193:113–21.CrossRefGoogle Scholar
  11. 11.
    Girometti R, Zuiani C, Toso F, Brondani G, Sorrentino D. MRI scoring system including dynamic motility evaluation in assessing the activity of Crohn’s disease of the terminal ileum. Acad Radiol. 2008;15:153–64.CrossRefGoogle Scholar
  12. 12.
    Sailer J, Peloschek P, Reinisch W, Vogelsang H, Turetschek K, Schima W. Anastomotic recurrence of Crohn’s disease after ileocolic resection: comparison of MR enteroclysis with endoscopy. Eur Radiol. 2008;18:2512–21.CrossRefGoogle Scholar
  13. 13.
    Hyun SB, Kitazume Y, Nagahori M, Toriihara A, Fujii T, Tsuchiya K, et al. Magnetic resonance enterocolonography is useful for simultaneous evaluation of small and large intestinal lesions in Crohn’s disease. Inflamm Bowel Dis. 2011;17:1063–72.CrossRefGoogle Scholar
  14. 14.
    Laghi A, Borrelli O, Paolantonio P, Dito L, Bueno de Mesquita M, Falconieri P, et al. Contrast enhanced magnetic resonance imaging of the terminal ileum in children with Crohn’s disease. Gut. 2003;52:393–7.CrossRefGoogle Scholar
  15. 15.
    Neye H, Voderholzer W, Rickes S, Weber J, Wermke W, Lochs H. Evaluation of criteria for the activity of Crohn’s disease by power Doppler sonography. Dig Dis. 2004;22:67–72.CrossRefGoogle Scholar
  16. 16.
    Drews B, Barth TFE, Hänle MM, Muche R, Pauls S, Klaus J, et al. Comparison of sonographically measured bowel wall vascularity, histology, and disease activity in Crohn’s disease. Eur Radiol. 2009;19:1379–86.CrossRefGoogle Scholar
  17. 17.
    Chiorean MV, Sandrasegaran K, Saxena R, Maglinte DD, Nakeeb A, Johnson CS. Correlation of CT enteroclysis with surgical pathology in Crohn’s disease. Am J Gastroenterol. 2007;102:2541–50.CrossRefGoogle Scholar
  18. 18.
    Faubion WA, Fletcher JG, Byrne SO, Feagan BG, De Villiers WJS, Salzberg B, et al. EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn’s disease activity: role of cross-sectional imaging. Am J Gastroenterol. 2013;108:1891–900.CrossRefGoogle Scholar
  19. 19.
    Rimola J, Rodriguez S, Garcia-Bosch O, Ordas I, Ayala E, Aceituno M, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut. 2009;58:1113–20.CrossRefGoogle Scholar
  20. 20.
    Rimola J, Ordás I, Rodriguez S, García-Bosch O, Aceituno M, Llach J, et al. Magnetic resonance imaging for evaluation of Crohnʼs disease. Inflamm Bowel Dis. 2011;17:1759–68.CrossRefGoogle Scholar
  21. 21.
    Ordás I, Rimola J, Rodríguez S, Paredes JM, Martínez-Pérez MJ, Blanc E, et al. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn’s disease. Gastroenterology. 2014;146:374–82.CrossRefGoogle Scholar
  22. 22.
    Stoppino LP, Della Valle N, Rizzi S, Cleopazzo E, Centola A, Iamele D, et al. Magnetic resonance enterography changes after antibody to tumor necrosis factor (anti-TNF) alpha therapy in Crohn’s disease: correlation with SES-CD and clinical-biological markers. BMC Med Imaging. 2016;16:1–9.CrossRefGoogle Scholar
  23. 23.
    Takenaka K, Ohtsuka K, Kitazume Y, Nagahori M, Fujii T, Saito E, et al. Correlation of the endoscopic and magnetic resonance scoring systems in the deep small intestine in Crohn’s disease. Inflamm Bowel Dis. 2015;21:1832–8.CrossRefGoogle Scholar
  24. 24.
    Steward MJ, Punwani S, Proctor I, Adjei-Gyamfi Y, Chatterjee F, Bloom S, et al. Non-perforating small bowel Crohn’s disease assessed by MRI enterography: derivation and histopathological validation of an MR-based activity index. Eur J Radiol. 2012;81:2080–8.CrossRefGoogle Scholar
  25. 25.
    Oussalah A, Laurent V, Bruot O, Bressenot A, Bigard M-A, Régent D, et al. Diffusion-weighted magnetic resonance without bowel preparation for detecting colonic inflammation in inflammatory bowel disease. Gut. 2010;59:1056–65.CrossRefGoogle Scholar
  26. 26.
    Hordonneau C, Buisson A, Scanzi J, Goutorbe F, Pereira B, Borderon C, et al. Diffusion-weighted magnetic resonance imaging in ileocolonic Crohn’s disease: validation of quantitative index of activity. Am J Gastroenterol. 2014;109:89–98.CrossRefGoogle Scholar
  27. 27.
    Buisson A, Pereira B, Goutte M, Reymond M, Allimant C, Obritin-Guilhen H, et al. Magnetic resonance index of activity (MaRIA) and Clermont score are highly and equally effective MRI indices in detecting mucosal healing in Crohn’s disease. Dig Liver Dis. 2017;49:1211–7.CrossRefGoogle Scholar
  28. 28.
    Dohan A, Taylor S, Hoeffel C, Barret M, Allez M, Dautry R, et al. Diffusion-weighted MRI in Crohn’s disease: current status and recommendations. J Magn Reson Imaging. 2016;44:1381–96.CrossRefGoogle Scholar
  29. 29.
    Rimola J, Alvarez-Cofiño A, Pérez-Jeldres T, Ayuso C, Alfaro I, Rodríguez S, et al. Comparison of three magnetic resonance enterography indices for grading activity in Crohn’s disease. J Gastroenterol. 2017;52:585–93.CrossRefGoogle Scholar
  30. 30.
    Tielbeek JAW, Makanyanga JC, Bipat S, Pendsé DA, Nio CY, Vos FM, et al. Grading Crohn disease activity with MRI: interobserver variability of MRI features, MRI scoring of severity, and correlation with Crohn disease endoscopic index of severity. AJR Am J Roentgenol. 2013;201:1220–8.CrossRefGoogle Scholar
  31. 31.
    Gecse KB, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, et al. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn’s disease. Gut. 2014;63:1381–92.CrossRefGoogle Scholar
  32. 32.
    Schwartz DA, Ghazi LJ, Regueiro M, Fichera A, Zoccali M, Ong EMW, et al. Guidelines for the multidisciplinary management of Crohnʼs perianal fistulas. Inflamm Bowel Dis. 2015;21:723–30.CrossRefGoogle Scholar
  33. 33.
    Horsthuis K, Ziech MLW, Bipat S, Spijkerboer AM, de Bruine-Dobben AC, Hommes DW, et al. Evaluation of an MRI-based score of disease activity in perianal fistulizing Crohn’s disease. Clin Imaging. 2011;35:360–5.CrossRefGoogle Scholar
  34. 34.
    Tozer P, Ng SC, Siddiqui MR, Plamondon S, Burling D, Gupta A, et al. Long-term MRI-guided combined anti-TNF and thiopurine therapy for Crohn’s perianal fistulas. Inflamm Bowel Dis. 2012;18:1825–34.CrossRefGoogle Scholar
  35. 35.
    Van Assche G, Vanbeckevoort D, Bielen D, Coremans G, Aerden I, Noman M, et al. Magnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn’s disease. Am J Gastroenterol. 2003;98:332–9.CrossRefGoogle Scholar
  36. 36.
    Bell S, Williams A, Wiesel P, Wilkinson K, Cohen R, Kamm M. The clinical course of fistulating Crohn’s disease. Aliment Pharmacol Ther. 2003;17:1145–51.CrossRefGoogle Scholar
  37. 37.
    Horsthuis K, Lavini C, Bipat S, Stokkers PC, Stoker J. Perianal Crohn disease: evaluation of dynamic contrast-enhanced MR imaging as an indicator of disease activity. Radiology. 2009;251:380–7.CrossRefGoogle Scholar
  38. 38.
    Savoye-Collet C, Savoye G, Koning E, Dacher JN, Lerebours E. Fistulizing perianal Crohn’s disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. Inflamm Bowel Dis. 2011;17:1751–8.CrossRefGoogle Scholar
  39. 39.
    Karmiris K, Bielen D, Vanbeckevoort D, Vermeire S, Coremans G, Rutgeerts P, et al. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn’s disease by using magnetic resonance imaging. Clin Gastroenterol Hepatol. 2011;9:130–6.CrossRefGoogle Scholar
  40. 40.
    Samaan MA, Puylaert CAJ, Levesque BG, Zou GY, Stitt L, Taylor SA, et al. The development of a magnetic resonance imaging index for fistulising Crohn’s disease. Aliment Pharmacol Ther. 2017;46:516–28.CrossRefGoogle Scholar
  41. 41.
    Pariente B, Mary J-Y, Danese S, Chowers Y, De Cruz P, D’Haens G, et al. Development of the Lémann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology. 2015;148:52–63.CrossRefGoogle Scholar
  42. 42.
    Gilletta C, Lewin M, Bourrier A, Nion-Larmurier I, Rajca S, Beaugerie L, et al. Changes in the Lémann index values during the first years of Crohn’s disease. Clin Gastroenterol Hepatol. 2015;13:1633–40.CrossRefGoogle Scholar
  43. 43.
    Fiorino G, Bonifacio C, Allocca M, Repici A, Balzarini L, Malesci A, et al. Bowel damage as assessed by the Lémann index is reversible on anti-TNF therapy for Crohn’s disease. J Crohns Colitis. 2015;9:633–9.CrossRefGoogle Scholar
  44. 44.
    Fiorino G, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A, et al. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis. 2017;11:274–80.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Department of RadiologyHospital Clínic of Barcelona, CIBEREHD, University of BarcelonaBarcelonaSpain

Personalised recommendations